Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00505778 · ClinicalTrials.gov registry record · Phase 3
A Comparison of Once a Day Dose Compared to 2 Doses/Day
A Phase 3 study of Ulcerative Colitis, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,027
- Enrollment target
- 20
- Study locations
NCT00505778 is a Phase 3 study of Ulcerative Colitis that has completed, run by Warner Chilcott. The registered enrollment target is 1,027 participants, below the 2,049-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT00505778, a Phase 3 study of Ulcerative Colitis, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,027 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy in maintaining remission of ulcerative colitis between a once daily (QD) Asacol regimen and a divided, twice daily (BID) Asacol dosing regimen.
Conditions Studied
Interventions
- DRUG Mesalamine Once-Daily
- DRUG Mesalamine Twice-Daily
Study Locations (20)
California
- Research Facility - Anaheim
- Research Facility - Beverly Hills
- Research Facility - Chico
- Research Facility - Encinitas
- Research Facility - Folsom
- Research Facility - La Mesa
- Research Facility - Lancaster
- Research Facility - Long Beach
- Research Facility - Los Angeles
- Research Facility - Los Angeles
Alabama
- Research Facility - Athens
- Research Facility - Birmingham
- Research Facility - Birmingham
- Research Facility - Dothan
Arizona
- Research Facility - Phoenix
- Research Facility - Scottsdale
- Research Facility - Tucson
- Research Facility - Tuscon
Arkansas
- Research Facility - Little Rock
- Research Facility - Lowell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,027 participants |
| Start Date | 2007-07 |
| Est. Completion | 2009-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00505778
The ClinicalTrials.gov registry entry for NCT00505778 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,027 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (50% lower). The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Mesalamine Once-Daily is the first listed.
NCT00505778 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00505778 about?
NCT00505778 is a clinical study titled "A Comparison of Once a Day Dose Compared to 2 Doses/Day". The purpose of this study is to compare the efficacy in maintaining remission of ulcerative colitis between a once daily (QD) Asacol regimen and a divided, twice daily (BID) Asacol dosing regimen.
What is the current status of trial NCT00505778?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,027 participants. The study started on 2007-07. Estimated completion is 2009-07.
What conditions does trial NCT00505778 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT00505778?
The interventions under investigation include: Mesalamine Once-Daily (DRUG), Mesalamine Twice-Daily (DRUG).
Who is sponsoring clinical trial NCT00505778?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00505778 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
RECRUITING · Phase 3
-
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RECRUITING · Phase 3
-
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
RECRUITING · Phase 3
-
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.